Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.37 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5977400 | 0.94 | P2RY2 (0.39) | P2RY2P2RY12P2RY1P2RY6P2RY4 | |
| SCHEMBL5977841 | 0.88 | TYMP (0.47) | P2RY2P2RY12P2RY1P2RY6P2RY14 | |
| SCHEMBL6854718 | 0.86 | L3MBTL1 (0.43) | P2RY2 | |
| SCHEMBL5709933 | 0.85 | P2RY2 (0.49) | P2RY2P2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL5978913 | 0.84 | P2RY2 (0.36) | P2RY2P2RY12P2RY4 | |
| SCHEMBL5977396 | 0.83 | TYMP (0.47) | P2RY2P2RY12P2RY1P2RY6P2RY14 | |
| SCHEMBL7719147 | 0.82 | P2RY14 (0.42) | P2RY2P2RY6P2RY14SLC28A1SLC28A2 | |
| SCHEMBL26359837 | 0.78 | TYMP (0.48) | P2RY2P2RY12P2RY1P2RY6P2RY14 | |
| SCHEMBL5314767 | 0.78 | P2RY2 (0.35) | P2RY2P2RY12P2RY6P2RY14SLC28A1 | |
| SCHEMBL30733465 | 0.76 | TYMP (0.46) | P2RY2P2RY12P2RY1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037646-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-6900297-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1487855-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6783931-B1 | FOR IMPROVED TRANSFER ACROSS CELLULAR MEMBRANES; FOR RESEARCH AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-08-31 | — | — | US | disclosed |
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | ISIS PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6753423-B1 | FOR PREFERENTIALLY MODULATED GENE EXPRESSION IN LIVER AND ASSOCIATED TISSUES | ISIS PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003072711-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-0728139-B1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-0728139-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995006659-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | FABP1, RNASE1, RNGTT | P2RY2 2930/4885P2RY12 2700/4885P2RY1 2832/4885 |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | FABP1, DCLRE1B, SLC10A1 | P2RY2 4396/4885P2RY12 4569/4885P2RY1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.